Smart blood tests may personalize lung cancer care after targeted therapy
NCT ID NCT04841811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a sensitive blood test (MRD) to guide follow-up treatment can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant stage III NSCLC). Participants first receive a targeted pill (aumolertinib), then a team of doctors decides on local therapy (surgery or radiation). After that, the blood test helps decide if maintenance therapy should continue. The goal is to see if this personalized approach works better and is safe. About 192 adults aged 18-70 with good performance status are being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTATION-POSITIVE UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Lung cancer institute
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing tube-free lung surgery tested for patients with fragile lungs
- Can standard cancer treatment wake up the immune system? a study investigates.
- Quitlines may double as lung cancer screening boosters
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Text messages and chatbots may help catch lung cancer earlier in underserved communities
- Shorter radiation course may reduce side effects for lung cancer patients